NEPHHealthcare · Medical Instruments & SuppliesThe 3 Wall Street analysts covering Nephros, Inc. hold a median 12-month price target of $6 — +36.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Nephros, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (93): The business earns solid, repeatable profits on what it owns.
Accruals (13): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NEPH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +36.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Aug 2025 | Maxim Group | Maintains | Buy | $4.50 → $6.00 |
| 12 Nov 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 15 May 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 8 Mar 2024 | Benchmark | Upgrade | Speculative Buy | — |
| 26 Jan 2021 | B. Riley FBR | Initiates | Buy | $13 |
| 26 Jan 2021 | B. Riley Securities | Initiates | Buy | — |
| 25 Nov 2020 | Benchmark | Initiates | Speculative Buy | — |
| 25 Nov 2020 | Maxim Group | Initiates | Buy | — |
| 24 Oct 2019 | Benchmark | Initiates | Speculative Buy | — |
| 4 Oct 2019 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NEPH appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Nephros, Inc. returned +5.5% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 31% of US stocks
Cheaper than 52% of US stocks
Cheaper than 29% of US stocks
Cheaper than 13% of US stocks
Higher than 81% of US stocks
Higher than 94% of US stocks
Higher than 71% of US stocks
Higher than 79% of US stocks
Higher than 66% of US stocks
Higher than 76% of US stocks
Higher than 86% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Nephros, Inc. has a market value of $44.3M and an enterprise value of $40.5M.
Revenue in the twelve months to 31 Mar 2026: $19.1M. The latest quarter grew 36.2% year on year.
Net income over the same four quarters: $776K, a 4.1% net margin.
Free cash flow in the twelve months to 31 Mar 2026: −$348K.
Trailing P/E: 25.5×; forward P/E: 19.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Nephros, Inc. employs 36 people — $531K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Nephros, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Nephros, Inc. held a Q2 2026 earnings call, and a transcript of the call was published by Seeking Alpha. The item announces the availability of the full earnings call transcript for the quarter.
Why it matters — A NEPH watcher would care because the earnings call transcript provides management's discussion of the company's Q2 2026 results and outlook.
Nephros, Inc. announced strong financial results for the quarter ended June 30, 2026, with record second-quarter net revenue growth of 36% to $6 million. Core programmatic revenue grew 27% year over year.
Why it matters — NEPH watchers would note the company's record quarterly revenue and continued year-over-year growth in its core programmatic business.
Nephros, Inc. announced it will file its second quarter 2026 financial results on Thursday, August 06, 2026 after market close and host a conference call that same day at 4:30pm ET. The company noted its focus on water filtration solutions for medical and commercial markets.
Why it matters — A NEPH watcher would care because the scheduled earnings release and conference call provide the next scheduled opportunity to review the company's second quarter financial performance.
The 3 Wall Street analysts covering Nephros, Inc. have a median 12-month price target of $6, with estimates ranging from $4.75 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Nephros, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nephros, Inc. 91 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Nephros, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (93 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +36.1% from the last close, and Ticker Nerd's factor model ranks Nephros, Inc. 91 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Nephros, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NEPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.75 to $8 over the next 12 months.
Nephros, Inc. returned +5.5% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Nephros Inc. is a company that specializes in the development and sale of filtration and ultrafiltration devices.
The most recent item we track (Seeking Alpha, 6 Aug 2026): "Nephros, Inc. (NEPH) Q2 2026 Earnings Call Transcript". Nephros, Inc. held a Q2 2026 earnings call, and a transcript of the call was published by Seeking Alpha. The item announces the availability of the full earnings call transcript for the quarter.
Nephros Inc. is a company that specializes in the development and sale of filtration and ultrafiltration devices. Primarily focusing on providing high-quality, robust filtration solutions, Nephros serves medical institutions, commercial facilities, and the military sector. The company's product portfolio includes hemodiafilters and ultrafilters, which are integral in kidney dialysis and ensuring water is adequately purified for various healthcare and industrial applications. Nephros's technological advancements in filtration enhance safety and operational efficiency, impacting sectors like healthcare equipment manufacturing, water treatment, and hospitality services. By addressing the critical need for clean water and advanced dialysis treatments, Nephros plays a vital role in both enhancing public health standards and improving patient outcomes in medical settings.
CEO Mr. Robert Banks · 36 employees · United States · https://www.nephros.com
